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Is the new GOLD classiﬁ cation applicable in China?
Chronic obstructive pulmonary disease (COPD) remains 
a major public health problem. The Global Strategy for 
the Diagnosis, Management, and Prevention of Chronic 
Obstructive Pulmonary Disease was ﬁ rst published by the 
Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) in 2001. A major revision was undertaken in 
2011 and an update to it was published in February 
this year.1 The Chinese Society of Respiratory Disease 
recently released new Chinese COPD guidelines,2 which 
recommend that the same strategy is used in China. 
However, whether this new system proves to be an 
improvement on the old system and whether it is 
applicable in China remains controversial and needs 
further research.
Many diﬀ erences exist between China and the 
developed countries that most of the GOLD committee 
members come from. 4·3 million people in China have 
COPD, and the disease prevalence is signiﬁ cantly higher in 
rural (8·8%) than in urban areas (7·8%; p=0·007).3 36·4% 
of practising Chinese doctors work at basic medical 
facilities (including community health service centres, 
small rural hospitals, village health rooms, clinics, and 
nurses’ stations). The educational level of these doctors 
is worrying. Of licensed doctors, only 8·3% have a post-
graduate degree and 43·6% have a bachelor’s degree. 
Thus, nearly half of all doctors in China have quite a low 
level of education, and the situation for licensed assistant 
doctors is even worse.4 Use of the GOLD criteria in China 
encounters several problems, as outlined below.
The assessment of symptoms in patients with COPD 
is based on either the modiﬁ ed Medical Research 
Council (mMRC) or the COPD Assessment Test score. 
In GOLD 2013, the Clinical COPD Questionnaire is also 
introduced. In clinical practice in China, 40–80 patients 
are seen per doctor per day, without enough nurses or 
physician assistants to help. Therefore, whichever is the 
easiest method to assess symptoms is judged to be the 
best. In one of our studies5 we enrolled 6437 patients 
in 329 hospitals across China and found that the COPD 
Assessment Test score was moderately correlated with 
mMRC dyspnoea grade (r=0·579, p<0·001). The most 
practical approach is for physicians to ask only one 
question—“do you feel breathless when walking?”—and 
quickly obtain the mMRC score. Therefore, use of only 
mMRC might be suitable for Chinese clinical practice. 
Spirometry is needed to diagnose COPD in the new 
GOLD 2011 criteria and spirometric tests are always 
important in the assessment of the disease. However, 
spirometry is not correctly or widely used in China. He 
and colleagues6 reported that only 50% of patients 
with COPD had ever had spirometry tests in tertiary 
hospitals, and only 18% had in primary or secondary 
hospitals. In our epidemiological survey in a rural area 
of Beijing,7 none of the 148 patients with COPD had 
ever undergone spirometry. This situation is due to 
inadequate physician knowledge about the disease 
and a scarcity of equipment in lower-level hospitals. A 
solution could be to use diﬀ erent methods in diﬀ erent 
hospitals. Although the GOLD criteria are suitable for 
use in tertiary hospitals, other methods such as peak 
expiratory ﬂ ow rate could be used instead in primary or 
secondary hospitals, since their sensitivity and speciﬁ city 
are quite good.8
The risk of exacerbation can be assessed in several 
ways: symptoms, use of medication, and admission 
to hospital. However, several questions remain to be 
answered in Chinese clinical practice. For example, 
the time of an acute exacerbation is often inaccurate 
because many patients have a poor understanding of 
the disease,7,9 and they might be unwilling or unable 
to write a COPD diary. Changes in medication, such 
as use of short-acting β2-agonists, antibiotics, or oral 
corticosteroids, might be strongly aﬀ ected by the 
knowledge of the physicians and the ﬁ nancial situation 
of the patients. In our study,7 none of the stable patients 
with COPD took inhalers regularly or as needed. During 
acute exacerbations, only 6·8% took theophylline and 
6·8% antibiotics. Another Chinese study9 reported 
similar results. However, in China, patients can obtain 
antibiotics easily. Many people keep antibiotics in 
reserve at home and they tend to show a preference for 
these drugs. Thus, use of antibiotics does not always 
indicate an acute exacerbation. Finally, the indication 
of hospital admission varies in diﬀ erent hospitals, and 
is aﬀ ected by socioeconomic factors, the health system, 
and policy. 
Inhaled corticosteroids, long-acting β-agonists, 
and long-acting muscarinic agonists are all expensive 
drugs and many patients in China cannot aﬀ ord them. 
An alternative pharmacological treatment for COPD, 
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phosphodiesterase-4 inhibitor, is awaiting approval by 
the China State Food and Drug Administration. In our 
2008 study,7 only 4·1% of stable patients with COPD 
took theophylline, and did so irregularly. Despite the 
fact that this study was done 5 years ago, the present 
situation is still not optimistic. Although most people 
living in rural areas have joined the New Rural Co-
operative Medical System of China, the proportion 
of reimbursement is quite low. For example, the 
reimbursement for admission to hospital is only 30% 
for tertiary hospitals and 40% for secondary hospitals in 
many regions. Thus, only patients with a high standard 
of living and a high level of education can follow the 
guidelines. We should have our own guidelines with 
patient stratiﬁ cation, and assessment of theophylline, 
carbocysteine, and other alternative drugs to make 
them more applicable in China. A basic version of 
treatment for COPD could be introduced (and would 
exist alongside the standard treatments), which would 
enable more general doctors to use available methods 
of diagnosis and treatment, and give patients in rural 
or remote areas the opportunity to have aﬀ ordable and 
appropriate treatment.
In conclusion, the GOLD 2011 criteria and the new 
COPD guidelines in China enable a better understanding 
of the eﬀ ects of the disease. However, the applicability of 
the GOLD criteria in China is still questionable. Perhaps 
future guidelines will expand these concepts by taking 
into account the characteristics of developing countries, 
and will be modiﬁ ed according to local clinical practice in 
diﬀ erent countries. 
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